Isolated Scapular Metastasis in a Patient with Malignant Struma Ovarii

Comunello, Juliane; Pinto, Fábio; Nakagawa, Suely Akiko; Chung, Wu Tu; Costa, Felipe D’Almeida; Brilhante, Américo Delgado

doi:10.2106/jbjs.cc.16.00262

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This report is the first in the literature to conclude that the outcome is related to the type of cancer. Studies have increasingly advocated for radioactive iodine therapy (12), but our study found that the mortality in the radioiodine treatment group was reduced by 1.5% compared with that in the patients who did not receive radioiodine treatment, but the difference was not statistically significant. As mentioned above, MSO is rare and difficult to find and diagnose, especially in those with nonpapillary thyroid cancer.…”

Section: Discussioncontrasting

confidence: 70%

“…Because it is prone to malignant transformation, the management of cases of MSO is still controversial. Most authors (11) have advocated for an aggressive treatment based on local surgery, followed by postoperative adjuvant treatment, including total thyroidectomy (12,13) and radioactive iodine 131 (I-131) therapy, especially when distant metastases are present.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical and Pathological Characteristics of Malignant Struma Ovarii: An Analysis of 144 Published Patients

et al. 2021

View full text Add to dashboard Cite

The objective of this study is to summarize the clinical and pathologic characteristics of malignant struma ovarii to facilitate the early diagnosis and treatment of this disease. All 144 patients were females from 27 countries. The mean age of the patients at diagnosis was 42.6 years. Overall, 35.71% of the patients underwent unilateral oophorectomy, 58.57% of the patients underwent bilateral oophorectomy, 5.72% of the patients were not ovariectomized, and 38.57% of the patients received radioactive iodine treatment with an average dose of 158.22 mCI each time. “Impure” types accounted for 70.19% of the cases, while pure types accounted for 29.81% of the cases. Among these cases, papillary thyroid carcinoma accounted for 50.00%, follicular thyroid carcinoma accounted for 26.47%, follicular variant of papillary thyroid carcinoma accounted for 18.63%, papillary and follicular mixed thyroid carcinoma accounted for 2.94%, anaplastic carcinoma accounted for 0.98%, and medullary carcinoma accounted for 0.98%. In total, 21 patients (51.22%) had elevated CA125. More than half of the patients (51.94%) had metastasis outside the ovary. The most common metastatic site was the pelvic cavity. The misdiagnosis rate was 17.27%. Mortality was related to metastasis and the cancer type. Gene mutations were found in the NRAS, KRAS, BRAF, and KIT genes and were similar to those in thyroid carcinoma, but some patients (37.5%) did not exhibit any gene mutations. Regardless of the treatment received, the survival rate is high. Treatment could initially include ovariectomy; however, in cases with metastasis and iodine uptake of the metastatic tumor, thyroidectomy, radioactive iodine therapy, and thyroid hormone inhibiting therapy are indicated.

show abstract

Section: Discussioncontrasting

confidence: 70%

Section: Introductionmentioning

confidence: 99%

The Clinical and Pathological Characteristics of Malignant Struma Ovarii: An Analysis of 144 Published Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Favorable survival rates (95.3%, 88.7%, and 88.7% at 5, 10, and 20 years of OS, respectively) were found regardless of treatment. Therefore, the overall prognosis of MSO is relatively good, but pulmonary and bone metastases of MSO have been reported in recent years [14, 15]. Therefore, all cases of MSO should be followed regularly for at least 10 years after operation and adjuvant therapies.…”

Section: Discussionmentioning

confidence: 99%

Malignant Struma Ovarii (Papillary Carcinoma) with Hyperthyroidism: A Case Report and Literature Review

Yang¹,

Zhong²,

Peng³

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

Malignant struma ovarii (MSO) is an extremely rare monodermal ovarian teratoma. Preoperative diagnosis and intraoperative freezing diagnosis are exceedingly difficult due to the rarity of the disease and its clinically noncharacteristic manifestations with less than 200 reports in the current literature. In this paper, a case of MSO (papillary carcinoma) with hyperthyroidism was discussed in terms of its epidemiology, clinicopathology, molecular features, treatment, and prognosis.

show abstract

Uncommon Metastases to and from the Musculoskeletal System

Bauer¹,

Harper²

2017

JBJS Case Connector

View full text Add to dashboard Cite

Isolated Scapular Metastasis in a Patient with Malignant Struma Ovarii

Cited by 4 publications

References 10 publications

The Clinical and Pathological Characteristics of Malignant Struma Ovarii: An Analysis of 144 Published Patients

The Clinical and Pathological Characteristics of Malignant Struma Ovarii: An Analysis of 144 Published Patients

Malignant Struma Ovarii (Papillary Carcinoma) with Hyperthyroidism: A Case Report and Literature Review

Uncommon Metastases to and from the Musculoskeletal System

Contact Info

Product

Resources

About